Form 8-K - Current report:
SEC Accession No. 0001279569-25-000119
Filing Date
2025-02-11
Accepted
2025-02-11 07:02:06
Documents
15
Period of Report
2025-02-11
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K form8k.htm   iXBRL 8-K 24757
2 NEWS RELEASE DATED FEBRUARY 11, 2025 ex991.htm EX-99.1 33428
3 GRAPHIC logo.jpg GRAPHIC 10685
  Complete submission text file 0001279569-25-000119.txt   253996

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE epix-20250211_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE epix-20250211_pre.xml EX-101.PRE 22363
6 XBRL SCHEMA FILE epix-20250211.xsd EX-101.SCH 3021
18 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 3772
Mailing Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5
Business Address SUITE 720 999 WEST BROADWAY VANCOUVER A1 V5Z 1K5 (778) 331-0962
ESSA Pharma Inc. (Filer) CIK: 0001633932 (see all company filings)

EIN.: 000000000 | State of Incorp.: A1 | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-37410 | Film No.: 25607653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)